ML-7

• UNSPSC Description:

  ML-7 is a myosin light chain kinase inhibitor with the activity to inhibit superoxide anion (O(2)(-)) release in human neutrophils. ML-7 can affect the activity of neutrophils independently of myosin light chain kinase. ML-7 inhibits the extracellular O(2)(-) release of stimulated cells, but has no effect on the intracellular O(2)(-) production. ML-7 also strongly inhibits the binding of the intracellular compartment of oxide production to the cell membrane, indicating that it plays a key role in stimulated neutrophils. At the same time, ML-7 protects cardiac function from ischemia/reperfusion injury[1].

• Target Antigen:

  Endogenous Metabolite

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/ml-7.html

• Smiles:

  O=S(N1CCNCCC1)(C2=C3C=CC=C(C3=CC=C2)I)=O

• Molecular Weight:

  416.28

• References & Citations:

  [1]ML-7 inhibits exocytosis of superoxide-producing intracellular compartments in human neutrophils stimulated with phorbol myristate acetate in a myosin light chain kinase-independent manner

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  109376-83-2